LifeMD, Inc. (NASDAQ:LFMD) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• LifeMD, Inc. has received an average rating of "Moderate Buy" from eight research firms, with two analysts rating it as hold, five as buy, and one as strong buy.
• The average 1-year price target for LifeMD stock among analysts is $13.17, reflecting differing views on its potential growth.
• CEO Justin Schreiber recently sold 25,000 shares at an average price of $13.38, indicating a 0.99% decrease in his overall position in the company.

LifeMD, Inc. (NASDAQ:LFMD - Get Free Report) has earned an average recommendation of "Moderate Buy" from the eight research firms that are presently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $13.1667.

Several equities research analysts have recently issued reports on the company. Wall Street Zen lowered LifeMD from a "buy" rating to a "hold" rating in a research report on Saturday, August 2nd. BTIG Research raised their target price on LifeMD from $15.00 to $18.00 and gave the company a "buy" rating in a research report on Wednesday, June 18th. Lake Street Capital decreased their target price on LifeMD from $18.00 to $14.00 and set a "buy" rating for the company in a research report on Wednesday, August 6th. KeyCorp decreased their target price on LifeMD from $14.00 to $12.00 and set an "overweight" rating for the company in a research report on Wednesday, August 6th. Finally, HC Wainwright decreased their target price on LifeMD from $14.00 to $13.00 and set a "buy" rating for the company in a research report on Thursday, August 7th.

LifeMD Trading Up 3.0%

Shares of LifeMD stock opened at $6.55 on Tuesday. LifeMD has a 1 year low of $3.99 and a 1 year high of $15.84. The firm has a market cap of $310.60 million, a PE ratio of -31.19 and a beta of 1.57. The stock has a fifty day moving average price of $7.74 and a 200-day moving average price of $8.58. The company has a debt-to-equity ratio of 9.21, a current ratio of 0.77 and a quick ratio of 0.72.

Insider Activity

In related news, CEO Justin Schreiber sold 25,000 shares of LifeMD stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $13.38, for a total value of $334,500.00. Following the completion of the sale, the chief executive officer owned 2,500,721 shares of the company's stock, valued at approximately $33,459,646.98. This trade represents a 0.99% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Nicholas P. Alvarez sold 75,000 shares of LifeMD stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $5.92, for a total value of $444,000.00. Following the completion of the sale, the insider directly owned 605,000 shares of the company's stock, valued at approximately $3,581,600. This trade represents a 11.03% decrease in their position. The disclosure for this sale can be found here. Company insiders own 18.40% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. CWM LLC boosted its stake in LifeMD by 17.5% in the 1st quarter. CWM LLC now owns 9,050 shares of the company's stock worth $49,000 after purchasing an additional 1,351 shares during the period. Nisa Investment Advisors LLC boosted its position in shares of LifeMD by 148.5% during the 2nd quarter. Nisa Investment Advisors LLC now owns 3,656 shares of the company's stock valued at $50,000 after acquiring an additional 2,185 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of LifeMD by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,647 shares of the company's stock valued at $270,000 after acquiring an additional 2,235 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in shares of LifeMD by 110.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,674 shares of the company's stock valued at $64,000 after acquiring an additional 2,452 shares during the last quarter. Finally, Uniplan Investment Counsel Inc. boosted its position in shares of LifeMD by 0.8% during the 1st quarter. Uniplan Investment Counsel Inc. now owns 388,288 shares of the company's stock valued at $2,112,000 after acquiring an additional 3,035 shares during the last quarter. Institutional investors own 35.52% of the company's stock.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.